Mainz Biomed N.V. Ordinary Shares - MYNZ STOCK NEWS

Welcome to our dedicated page for Mainz Biomed N.V. Ordinary Shares news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V. Ordinary Shares stock.

Mainz Biomed N.V. (symbol: MYNZ) is a pioneering company in the field of molecular genetic diagnostics, dedicated to providing patient-friendly testing solutions for life-threatening conditions. With a mission to improve early detection rates and thereby save lives through science, Mainz Biomed develops market-ready products that are both accurate and easy to use.

One of their key innovations is ColoAlert®, a non-invasive, at-home screening test for colorectal cancer (CRC). Utilizing real-time Polymerase Chain Reaction (PCR) to detect molecular-genetic biomarkers in stool samples, ColoAlert® offers high sensitivity and specificity. This test is available in select European countries and is poised for FDA approval in the United States through the ongoing 'ReconAAsense' clinical trial.

Mainz Biomed aims to expand its market reach by fostering partnerships with laboratories and healthcare providers. The company is also committed to advancing the early detection of other cancers, including pancreatic cancer, through products like PancAlert, which is currently in early stages of development.

Recently, Mainz Biomed showcased ColoAlert® at the UDH Congress, emphasizing its role in enhancing comprehensive health strategies. The company reported a 69% year-over-year revenue increase for ColoAlert® and maintained a stable financial condition with a $7.1 million cash balance at year-end.

In collaboration with healthcare professionals, Mainz Biomed continues to contribute to scientific research and knowledge exchange. This commitment was highlighted by their latest clinical studies, ColoFuture and eAArly DETECT, which demonstrated extraordinary statistical significance in CRC and advanced adenoma detection.

For more details, visit Mainz Biomed's official website at www.mainzbiomed.com.

02/22/2024 08:01 AM

News

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Praxisdienst, Germany's largest online retailer, to distribute their innovative early cancer detection product ColoAlert®, enhancing healthcare delivery in Germany. The collaboration aims to provide a more comprehensive screening option for colorectal cancer, utilizing advanced technology for higher detection rates.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.96%

Tags

02/21/2024 08:01 AM

News

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Rhea-AI Summary

Mainz Biomed (NASDAQ: MYNZ) partners with TomaLab to launch ColoAlert® in Italy, revolutionizing colorectal cancer detection. ColoAlert® offers a highly effective at-home test for early cancer detection, improving survival rates in Italy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.97%

Tags

02/06/2024 08:01 AM

News

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) announces the opening of the 'European Oncology Lab' (EOL), a physician-led facility in Saarland, Germany, offering ColoAlert® as a laboratory medical service directly to physicians and patients. This expansion aims to make early colorectal cancer (CRC) detection more accessible for the approximately 8.7 million individuals covered by private health insurance in Germany. The new revenue growth opportunity is expected to complement the company's established commercial sales channels, coinciding with Colorectal Cancer Awareness Month in March.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.23%

Tags

01/11/2024 08:01 AM

News

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Rhea-AI Summary

Mainz Biomed N.V. (MYNZ) reaffirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium to advance innovative colorectal cancer detection in Poland. The company aims to increase treatment options and survival rates through early detection. Mainz Biomed and TestDNA will be present as exhibitors and open the second day of panel discussions. The symposium gathers national Polish lecturers, scientists, and practitioners to share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.68%

Tags

01/09/2024 08:01 AM

News

Mainz Biomed Provides Year-End Corporate Review 2023

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) reported groundbreaking results from ColoFuture and eAArly DETECT studies, expanded international commercialization of ColoAlert®, and announced a year-end summary of corporate and product development progress.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.35%

Tags

12/19/2023 08:01 AM

News

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Hermann Bantleon GmbH to offer ColoAlert® At-Home Screening Test to employees across all three German locations in Q1 2024

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/12/2023 08:01 AM

News

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) actively participates in two significant gastroenterology conferences in Poland alongside TestDNA, showcasing their flagship product ColoAlert® for colorectal cancer detection and emphasizing the need for earlier detection strategies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.87%

Tags

12/05/2023 09:01 AM

News

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) announced groundbreaking results from its eAArly DETECT U.S. clinical study, reporting a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. The study supports the inclusion of novel mRNA biomarkers in a pivotal FDA clinical trial, positioning the next generation ColoAlert® as a robust and accurate at-home CRC diagnostic screening test on the market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-24.53%

Tags

11/29/2023 08:01 AM

News

Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present at the 35th Annual Piper Sandler Healthcare Conference. The presentation by CEO Guido Baechler and CFO Bill Caragol will be available for live viewing and post-event webcast. The conference aims to bring together industry executives, investors, and professionals to explore critical trends and identify impactful leaders in the healthcare market. Baechler and Caragol will also be available for 1-on-1 meetings with investors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.82%

Tags

11/20/2023 08:01 AM

News

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) announces that its CEO and CFO will present at the 35th Annual Piper Sandler Healthcare Conference in New York, NY, USA. The conference aims to bring together industry executives, investors, and professionals to explore critical healthcare trends. Mainz Biomed's presentation is scheduled for November 29th at 8.50am ET, with opportunities for 1-on-1 meetings with investors throughout the day.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.13%

Tags

FAQ

What is the current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ) is $0.2271 as of November 1, 2024.

What is the market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ) is approximately 5.8M.

What does Mainz Biomed specialize in?

Mainz Biomed specializes in developing molecular genetic diagnostic solutions for early detection of life-threatening conditions, such as colorectal and pancreatic cancers.

What is ColoAlert®?

ColoAlert® is Mainz Biomed's flagship product, a non-invasive, at-home test for colorectal cancer that uses PCR technology to detect molecular-genetic biomarkers in stool samples.

Where is ColoAlert® available?

ColoAlert® is currently available in select European countries and is undergoing FDA approval for the U.S. market.

What recent achievements has Mainz Biomed made?

Mainz Biomed recently presented significant clinical study results at the UDH Congress and reported a 69% year-over-year revenue increase for ColoAlert®.

What is the ReconAAsense trial?

The ReconAAsense trial is Mainz Biomed's FDA-registration study designed to evaluate ColoAlert® for U.S. regulatory approval.

What other products does Mainz Biomed have in development?

Apart from ColoAlert®, Mainz Biomed is developing PancAlert, an early-stage screening test for pancreatic cancer.

How does ColoAlert® differ from other CRC screening tests?

ColoAlert® offers higher accuracy and earlier detection rates compared to traditional fecal occult blood tests (FOBT), thanks to its advanced PCR-based technology.

What is Mainz Biomed’s mission?

Mainz Biomed's mission is to save lives through science by providing accurate, easy-to-use diagnostic solutions for early detection of deadly conditions.

How does Mainz Biomed contribute to the healthcare sector?

Mainz Biomed contributes through scientific research, innovative diagnostic solutions, and partnerships with healthcare professionals to improve early detection and patient care.